| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/01.AIDS.0000194799.43799.EA |
| P698 | PubMed publication ID | 16284461 |
| P50 | author | Josep Maria Gatell | Q17030537 |
| Bonaventura Clotet Sala | Q20100355 | ||
| Jens Lundgren | Q42325404 | ||
| Amanda Mocroft | Q47006497 | ||
| Jürgen Rockstroh | Q47006499 | ||
| Stéphane De Wit | Q47006685 | ||
| EuroSIDA Study Group | Q47159116 | ||
| Vicente Soriano | Q55277832 | ||
| Andrew N Phillips | Q87677848 | ||
| Peter Reiss | Q92970863 | ||
| Ole Kirk | Q102213445 | ||
| P433 | issue | 18 | |
| P304 | page(s) | 2117-2125 | |
| P577 | publication date | 2005-12-01 | |
| P1433 | published in | AIDS | Q4651863 |
| P1476 | title | Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? | |
| P478 | volume | 19 |
| Q30648896 | "Without a mother": caregivers and community members' views about the impacts of maternal mortality on families in KwaZulu-Natal, South Africa |
| Q30574483 | Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study |
| Q37096947 | Antiretroviral therapy : pharmacokinetic considerations in patients with renal or hepatic impairment |
| Q37579940 | Antiretroviral therapy reduces the rate of hepatic decompensation among HIV- and hepatitis C virus-coinfected veterans |
| Q35980035 | Association of Patients' Geographic Origins with Viral Hepatitis Co-infection Patterns, Spain. |
| Q34602914 | At what time and with which combinations should maraviroc be indicated in the new antiretroviral treatment scenario? |
| Q37013998 | Brief Report: Highly Active Antiretroviral Therapy Mitigates Liver Disease in HIV Infection |
| Q36745251 | CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection |
| Q37353573 | Cardiovascular complications in HIV management: past, present, and future |
| Q37132597 | Chronic hepatitis B and C co-infection increased all-cause mortality in HAART-naive HIV patients in Northern Thailand |
| Q30418874 | Circulating miRNA-122 levels are associated with hepatic necroinflammation and portal hypertension in HIV/HCV coinfection |
| Q43039596 | Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. |
| Q36875697 | Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study |
| Q44044896 | Could anti-HCV treatment prevent recurrence of hepatocellular carcinoma in HIV-infected patients? Two case reports |
| Q40023495 | Epidemiology of hepatitis D virus (HDV) infection in an urban area of northern Italy |
| Q34260569 | HIV and hepatitis C co-infection in Europe, Israel and Argentina: a EuroSIDA perspective |
| Q37541128 | Haemoglobin and anaemia in the SMART study |
| Q41934626 | Hepatitis B, hepatitis C and mortality among HIV-positive individuals |
| Q37481988 | Hepatitis C Virus and HIV Type 1 Co-Infection |
| Q34168504 | Hepatitis C virus infection in the human immunodeficiency virus infected patient |
| Q58945453 | Hepatitis delta in Europe: Vanishing or refreshing? |
| Q45356161 | Human immunodeficiency virus and hepatitis C virus coinfection: the agenda is full while waiting for new drugs |
| Q35156330 | Hyaluronic acid levels predict increased risk of non-AIDS death in hepatitis-coinfected persons interrupting antiretroviral therapy in the SMART Study |
| Q34147433 | Immune response to hepatitis B vaccine in HIV-infected subjects using granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant: ACTG study 5220. |
| Q36997773 | Inflammation and repair in viral hepatitis C. |
| Q59330593 | Liver as a target of human immunodeficiency virus infection |
| Q45408633 | Lopinavir/ritonavir pharmacokinetics in HIV and hepatitis C virus co-infected patients without liver function impairment: influence of liver fibrosis. |
| Q30433644 | MELD score is an important predictor of pretransplantation mortality in HIV-infected liver transplant candidates |
| Q37089277 | Maternal mortality in rural South Africa: the impact of case definition on levels and trends |
| Q35834104 | Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy |
| Q34268818 | PRO-C3-levels in patients with HIV/HCV-Co-infection reflect fibrosis stage and degree of portal hypertension |
| Q34802712 | Perceptions of alcohol risk among individuals living with HIV. |
| Q34723368 | Protective effect of pregnancy in rural South Africa: questioning the concept of "indirect cause" of maternal death |
| Q37046208 | Reduced healthcare utilization following successful hepatitis C virus treatment in HIV-co-infected patients with mild liver disease |
| Q37418140 | Serious Non-AIDS events: Immunopathogenesis and interventional strategies |
| Q36592765 | Solid organ transplantation is a reality for patients with HIV infection |
| Q36035557 | The effect of HIV infection, immunodeficiency, and antiretroviral therapy on the risk of hepatic dysfunction |
| Q57127580 | The elevated prevalence of risk factors for chronic liver disease among ageing people with hemophilia and implications for treatment |
| Q37186467 | The role of HIV in serious diseases other than AIDS. |
| Q42379032 | Transient elastography: a non-invasive tool for assessing liver fibrosis in HIV/HCV patients |
| Q28477366 | Trouble with bleeding: risk factors for acute hepatitis C among HIV-positive gay men from Germany--a case-control study |
Search more.